Home Newsfeeds Jefferies Downgrades Roku to Underperform, Lowers Price Target to $30

Jefferies Downgrades Roku to Underperform, Lowers Price Target to $30

Jefferies analyst Andrew Uerkwitz downgrades Roku (NASDAQ:ROKU) from Hold to Underperform and lowers the price target from $45 to $30.

byBenzinga Newsdesk

January 12, 2023

1 minute read

Jefferies analyst Andrew Uerkwitz downgrades Roku (NASDAQ:ROKU) from Hold to Underperform and lowers the price target from $45 to $30.

Arm Files For Nasdaq Listing: Here’s What’s Going On

By Ryan Gustafson

August 21, 5:25 PM

The chipmaker Arm filed for a Nasdaq listing on Monday, seeking to trade under the ticker symbol "ARM."

NVDA

Soleno Therapeutics Announces Initiation Of Randomized Withdrawal Study Of DCCR For Treatment Of Prader-Willi Syndrome

By Benzinga Newsdesk

October 3, 8:09 AM

Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a

SLNO

UPDATE: Quantum-Si Q4 Adj. EPS $(0.17) Beats $(0.20) Estimate

By Happy Mohamed

March 6, 9:09 AM

Quantum-Si (NASDAQ:QSI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15 percent. This is a 19.05 percent increase over losses of $(0.21) per share from the same

QSI

Several S&P 500 Companies Step Up Capital Spending Faster Than Share Buybacks

By Vandana Singh

August 4, 7:58 AM

Big U.S. companies, including Alphabet Inc (NASDAQ:GOOG), General Motors Company (NYSE:GM), and PepsiCo Inc (NASDAQ:PEP), have increased spending on real estate, equipment, and technology.…

Jefferies Downgrades Roku to Underperform, Lowers Price Target to $30

Related Posts

Arm Files For Nasdaq Listing: Here’s What’s Going On

Soleno Therapeutics Announces Initiation Of Randomized Withdrawal Study Of DCCR For Treatment Of Prader-Willi Syndrome

UPDATE: Quantum-Si Q4 Adj. EPS $(0.17) Beats $(0.20) Estimate

Several S&P 500 Companies Step Up Capital Spending Faster Than Share Buybacks